{{noteTA
|G1=LS
|1=zh-hans:新斯的明;zh-tw:新斯狄明
}}
{{Unreferenced|time=2021-10-08T03:00:24+00:00}}
{{medical}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 401609488
| IUPAC_name = 3-{[(dimethylamino)carbonyl]oxy}-''N,N,N''-trimethylbenzenaminium
| image = Neostigmine Ion V.1.svg

<!--Clinical data-->
| tradename = Prostigmin
| Drugs.com = {{drugs.com|monograph|neostigmine-bromide}}
| pregnancy_category =  
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability = 不清楚，可能低于5%
| metabolism = 会被乙酰胆碱酯酶或血浆酯酶缓慢水解
| elimination_half-life = 50～90分钟
| excretion = 从尿液排出，其中：药物无变化排出多达70%，醇代谢产物达30%

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 59-99-4
| ATC_prefix = N07
| ATC_suffix = AA01
| ATC_supplemental = {{ATC|S01|EB06}} {{ATCvet|A03|AB93}}
| PubChem = 4456
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB01400
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4301
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3982TWQ96G
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D08261
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 7514
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 54126

<!--Chemical data-->
 | C=12 | H=19 | N=2 | O=2 
| molecular_weight = 223.294 g/mol
| smiles = O=C(Oc1cccc(c1)[N+](C)(C)C)N(C)C
| InChI = 1/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1
| InChIKey = ALWKGYPQUAPLQC-UHFFFAOYAL
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ALWKGYPQUAPLQC-UHFFFAOYSA-N
}}

'''新斯的明'''（{{lang-en|Neostigmine}}）是一种[[拟副交感神经药|拟副交感神经药]]，其作用机理是作为一种[[易逆乙酰胆碱酯酶抑制药|易逆乙酰胆碱酯酶抑制药]]。
:常用于[[肌无力|肌无力]]和术后腹水潴留，也可用于[[竞争性神经肌肉阻滞药|竞争性神经肌肉阻滞药]]解毒
:禁用于[[肠梗阻|机械性肠梗阻]]，[[尿路梗阻|尿路梗阻]]一类患者

[[Category:乙酰胆碱酯酶抑制剂|Category:乙酰胆碱酯酶抑制剂]]
[[Category:氨基甲酸芳香酯|Category:氨基甲酸芳香酯]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]